文献速递糖尿病

厄图格列净对2型糖尿病患者肾脏复合结局、肾功能及白蛋白尿的影响:VERTIS CV随机试验分析

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
PubMed 文献 · Diabetologia · 2021-03-04

VERTIS CV试验纳入8246例2型糖尿病合并动脉粥样硬化性心血管疾病患者,随机接受厄图格列净5mg或15mg(合并分析)或安慰剂,平均随访3.5年。预设探索性肾脏复合终点(eGFR持续下降40%、慢性透析/移植或肾死亡)风险显著降低(HR 0.66,95%CI 0.50-0.88)。厄图格列净还降低UACR并减缓eGFR下降。

要点

  • 厄图格列净降低探索性肾脏复合终点风险(HR 0.66)。
  • 厄图格列净降低UACR并减缓eGFR下降。
  • 亚组分析提示大量白蛋白尿和KDIGO高危者获益更明显。

核心结论

  • 在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,厄图格列净降低预设探索性肾脏复合终点风险,并有助于保留eGFR和降低UACR。

研究设计与样本

  • VERTIS CV随机对照试验(NCT01986881),纳入8246例2型糖尿病合并动脉粥样硬化性心血管疾病患者,随机接受厄图格列净5mg或15mg(合并分析)或安慰剂,平均随访3.5年。

主要发现

  • 探索性肾脏复合终点(eGFR持续下降40%、慢性透析/移植或肾死亡)事件率在厄图格列净组为6.0/1000人年,安慰剂组为9.0/1000人年;HR 0.66(95%CI 0.50-0.88)。
  • 60个月时,厄图格列净组UACR较基线变化(安慰剂校正)为-16.2%(95%CI -23.9至-7.6),eGFR变化为2.6 ml min-1 [1.73 m]-2(95%CI 1.5至3.6)。
  • 亚组分析显示厄图格列净一致降低UACR并减缓eGFR下降,大量白蛋白尿和KDIGO慢性肾病高/极高危亚组效果可能更明显。

临床怎么用

  • 对于2型糖尿病合并动脉粥样硬化性心血管疾病患者,厄图格列净可能有助于降低肾脏复合终点风险、降低白蛋白尿并减缓肾功能下降。

局限性

  • 探索性肾脏复合终点为预设探索性分析,需谨慎解释。
  • 研究人群限于2型糖尿病合并动脉粥样硬化性心血管疾病患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with ertugliflozin compared with placebo as 0.81 (0.63, 1.04). The effect of ertugliflozin on exploratory kidney-related outcomes was evaluated using data from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881). METHODS: Individuals with type 2 diabetes mellitus and established atherosclerotic CVD were randomised to receive ertugliflozin 5 mg or 15 mg (observations from both doses were pooled), or matching placebo, added on to existing treatment. The kidney composite outcome in VERTIS CV (reported previously) was time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death. The pre-specified exploratory composite outcome replaced doubling of serum creatinine with sustained 40% decrease from baseline in eGFR. In addition, the impact of ertugliflozin on urinary albumin/creatinine ratio (UACR) and eGFR over time was assessed. RESULTS: A total of 8246 individuals were randomised and followed for a mean of 3.5 years. The exploratory kidney composite outcome of sustained 40% reduction from baseline in eGFR, chronic kidney dialysis/transplant or renal death occurred at a lower event rate (events per 1000 person-years) in the ertugliflozin group than with the placebo group (6.0 vs 9.0); the HR (95% CI) was 0.66 (0.50, 0.88). At 60 months, in the ertugliflozin group, placebo-corrected changes from baseline (95% CIs) in UACR and eGFR were -16.2% (-23.9, -7.6) and 2.6 ml min-1 [1.73 m]-2 (1.5, 3.6), respectively. Ertugliflozin was associated with a consistent decrease in UACR and attenuation of eGFR decline across subgroups, with a suggested larger effect observed in the macroalbuminuria and Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease (KDIGO CKD) high/very high-risk subgroups. CONCLUSIONS/INTERPRETATION: Among individuals with type 2 diabetes and atherosclerotic CVD, ertugliflozin reduced the risk for the pre-specified exploratory composite renal endpoint and was associated with preservation of eGFR and reduced UACR. TRIAL REGISTRATION: ClinicalTrials.gov NCT01986881.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Cherney DZI, Charbonnel B, Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021. PMID: 33665685. doi:10.1007/s00125-021-05407-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。